FDA Adverse Event Malfunction Summary report: N

MYNX CADENCE VASCULAR CLOSURE DEVICE 5F

MDR report key: 2840269 · Received April 19, 2012

Report

Report Number
3004939290-2012-00077
Event Type
Malfunction
Date Received
April 19, 2012
Date of Event
March 23, 2012
Report Date
March 23, 2012
Manufacturer
ACCESSCLOSURE, INC.
Product Code
MGB
PMA / PMN Number
P040044
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
IL, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

THE DEVICE AND THE PROCEDURAL SHEATH WERE NOT RETURNED: THEREFORE, A PHYSICAL INVESTIGATION COULD NOT BE PERFORMED. BASED ON THE INFORMATION PROVIDED AND NO RETURNED DEVICE FOR PHYSICAL INVESTIGATION, THE REPORTED EVENT COULD NOT BE CONFIRMED AND THE ROOT CAUSE COULD NOT BE DETERMINED. THE REVIEW OF THE LHR (LOT F1204402) INDICATED THAT THE DEVICE LOT MET ALL ESTABLISHED PERFORMANCE CRITERIA PRIOR TO SHIPMENT.

Description of Event or Problem · 1

IT WAS REPORTED BY THE ACI CLINICAL SPECIALIST THAT A (B)(6) FEMALE PATIENT UNDERWENT AN INTERVENTIONAL PROCEDURE ON (B)(6) 2012. ACCESS WAS OBTAINED AT THE COMMON FEMORAL ARTERY WITH A 5F TERUMO PINNACLE SHEATH. PRE-PROCEDURE FEMORAL ANGIOGRAM REVEALED NO EVIDENCE OF CALCIUM OR PVD IN THE VICINITY OF THE PUNCTURE SITE. POST PROCEDURE, THE PHYSICIAN WHO IS IN TRAINING WITH THE MYNX, SELECTED THE MYNX CADENCE VASCULAR CLOSURE DEVICE 5F TO CLOSE THE ACCESS SITE. IT WAS REPORTED THAT AFTER SHUTTLING DOWN TO THE HARD STOP, THE PHYSICIAN RETRACTED THE SHEATH ACCORDING TO THE IFU AND THE ADVANCER TUBE DID NOT ENGAGE. THE PHYSICIAN ELECTED TO DEFLATE THE BALLOON AND REMOVED THE DEVICE. THE PATIENT WAS SUBSEQUENTLY CONVERTED TO 10 MINUTES OF MANUAL COMPRESSION WITH NO ADVERSE EVENT OR FURTHER COMPLICATIONS. THE PATIENT WAS DISCHARGED TO HOME WITH NO CLINICAL SEQUELA. NO ADDITIONAL INFORMATION WAS PROVIDED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 MYNX CADENCE VASCULAR CLOSURE DEVICE 5F MGB ACCESSCLOSURE, INC. MX5001 F1204402

Patients

Seq Age Sex Outcome Treatment
1 62 YR